⌘K
Loading ticker…
As of 2026-08-24, Ginkgo Bioworks Holdings, Inc. (DNA) has a 3-month relative strength percentile of 21 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 41. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.6%, relative volume 0.91×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
DNA is held by 16 ETFs as of May 2026. Top owner: VTWO at 0.01% weight, $2M notional. Top 3 carry $5M.
Held by 41 ETFs · $40M across latest filings · largest weight 0.84% (THNQ).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.01% | $2M | — |
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $2M | — |
| VHTVanguard Health Care ETF | 0.01% | $971K | — |
| AVSC | 0.03% | $857K | — |
| ISMD | 0.26% | $822K | +0.11 pp |
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.02% |
| $292K |
| — |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $248K | — |
| VTHRVanguard Russell 3000 ETF | 0.00% | $31K | — |
| VTWG | 0.00% | $23K | — |
| MSSM | 0.00% | $19K | — |
Showing 10 of 16 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DNA Jan avg: 7.74% median: 11.66% win: 75% σ: 26.87% n: 4 2022-04-12 → 2026-07-31 | DNA Feb avg: -15.52% median: -24.68% win: 25% σ: 28.17% n: 4 2022-04-12 → 2026-07-31 | DNA Mar avg: -18.30% median: -16.60% win: 0% σ: 10.74% n: 4 2022-04-12 → 2026-07-31 | DNA Apr avg: 4.49% median: -8.27% win: 40% σ: 27.33% n: 5 2022-04-12 → 2026-07-31 | DNA May avg: 0.02% median: 6.21% win: 60% σ: 26.04% n: 5 2022-04-12 → 2026-07-31 | DNA Jun avg: 5.18% median: 5.76% win: 60% σ: 38.43% n: 5 2022-04-12 → 2026-07-31 | DNA Jul avg: 13.44% median: 16.80% win: 80% σ: 19.56% n: 5 2022-04-12 → 2026-07-31 | DNA Aug avg: -18.07% median: -6.36% win: 0% σ: 25.31% n: 4 2022-04-12 → 2026-07-31 (current) | DNA Sep avg: 7.56% median: 15.53% win: 75% σ: 20.36% n: 4 2022-04-12 → 2026-07-31 | DNA Oct avg: -13.55% median: -11.70% win: 0% σ: 7.61% n: 4 2022-04-12 → 2026-07-31 | DNA Nov avg: -11.83% median: -16.47% win: 25% σ: 20.21% n: 4 2022-04-12 → 2026-07-31 | DNA Dec avg: 4.59% median: 1.21% win: 50% σ: 21.44% n: 4 2022-04-12 → 2026-07-31 |